Login
$OPK
$1.61 -$0.02 (1.23%) Close

$OPK 3 SEC Filings

Filed On Filing
20 Mar 2026 Form 3: Uppaluri Subbarao V, Director

Holds 622,817 shares of Common Stock

11 May 2022 Form 3: Nabel Gary J., Director

Holds 0 shares of Common Stock

11 May 2022 Form 3: Zerhouni Elias A., Director

Holds 0 shares of Common Stock

11 May 2022 Form 3: Borisy Alexis, Director

Holds 0 shares of Common Stock

09 May 2022 Form 3: Opko HEALTH, Inc., 10% owner · GeneDx Holdings Corp.

Holds 80,000,000 shares of Class A Common Stock, par value $0.0001 per share

03 Mar 2021 Form 3: Lachman Prem A, Director

Holds 0 shares of Common Stock

21 Dec 2020 Form 3: Medel Roger Md, Director

No securities owned

24 Jul 2020 Form 3: Hernandez Rulfo Fernando, CAO, Treasurer

Holds 87 shares of Common Stock

24 Jul 2020 Form 3: Cohen Jon R, Director

Holds 75,000 shares of Common Stock

08 Jan 2020 Form 3: Japour Anthony J, Director

No securities owned

04 Apr 2018 Form 3: Fishel Robert Scott, Director

Holds 4,001,428 shares of Common Stock

09 Nov 2017 Form 3: Opko Health, Inc., 10% owner · VBI Vaccines Inc/BC

Holds 6,023,014 shares of Common Stock

04 Aug 2017 Form 3: Opko Health, Inc., 10% owner · Eloxx Pharmaceuticals Inc

Holds 10,517,016 shares of Common Stock

10 Feb 2017 Form 3: Krasno Richard M, Director

Holds 73,333 shares of Common Stock

17 Mar 2014 Form 3: Opko Health, Inc., 10% owner · Cocrystal Pharma Inc

Holds 18,696,301 shares of Common Stock

13 Mar 2013 Form 3: Opko Health, Inc., 10% owner · Phio Pharmaceuticals Corp

Holds 67,241,380 shares of Common Stock

18 Jul 2012 Form 3: Rodriguez Juan F, Sr. Vice President, CFO

No securities owned

15 Jun 2012 Form 3: Kolosov Dmitry, Director

No securities owned

22 Sep 2009 Form 3: Opko Health, Inc., 10% owner · Sorrento Therapeutics, Inc.

Holds 59,015,257 shares of Common Stock

23 Apr 2009 Form 3: Yu Alice Lin-Tsing, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support